Display Settings:

Format

Send to:

Choose Destination

    Sao Paulo Med J. 1998 Nov-Dec;116(6):1882-4.

    Esophageal ulcer and alendronate.

    Ferrari Júnior AP, Domingues SH.

    Division of Gastroenterology, Universidade Federal de São Paulo/Escola Paulista de Medicina, Brazil. angelo@gastro.epm.br

    OBJECTIVE: To describe a case of esophageal ulcer associated with the use of alendronate. CASE REPORT: This is the fifth case ever described in the literature according to our bibliographic review. In our patient, the association between the drug and the esophageal lesions was masked by the presence of a hiatal hernia, potentially a cause of the esophageal lesion. The persistence of the lesions despite high doses of anti-reflux therapy called attention to the possibility of the relationship. The esophageal lesion healed soon after suspension of alendronate. DISCUSSION: The authors present a review of the literature and point to the need for diagnostic investigation, to suspend such a drug from patients who experience dyspeptic symptoms while using it.

    PMID: 10349198 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Alendronate (Fosamax®, Fosamax Plus D®)

      Alendronate is used to treat and prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause ('change of life,' end of menstrual periods) and to treat...